Tegsedi - What matters is now

Home

Home

For your hATTR patients, what matters is now


Tegsedi can significantly delay disease progression, and it is the first and only subcutaneous treatment to target the disease at its source.1

With Tegsedi, patients have the independence to self-administer at a time and place that works for them.1

For your hATTR patients with stage 1 or 2 polyneuropathy. The priority isn’t only what lies ahead. It’s defending what is still here.

testimage

Learn more
About hATTR

About hATTR

Hereditary transthyretin amyloidosis is a rapidly progressive and life-shortening disease

About Tegsedi

About Tegsedi

For your hATTR patients with stage 1 or 2 polyneuropathy, what matters is now

Tegsedi CONNECT

Tegsedi CONNECT

Empowering independence for people living with hATTR

Prescribing information

Prescribing information

 

References
  1. Tegsedi Summary of Product Characteristics. June 2021. 2. Benson MD et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):22–31.